<br>HELLS 是一种染色质重塑剂，在胰腺癌中高表达，其下调会损害肿瘤生长，并通过重新表达肿瘤抑制因子 TGFBR3 来对顺铂敏感,Cancer Medicine

当前位置： X-MOL 学术 › Cancer Med. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

HELLS 是一种染色质重塑剂，在胰腺癌中高表达，其下调会损害肿瘤生长，并通过重新表达肿瘤抑制因子 TGFBR3 来对顺铂敏感
Cancer Medicine ( IF 2.9 ) Pub Date : 2020-12-06 , DOI: 10.1002/cam4.3627
Xuyang Hou ₁ , Leping Yang ₁ , Kunpeng Wang ₂ , Yan Zhou ₁ , Qinglong Li ₁ , Fanhua Kong ₁ , Xi Liu ₁ , Jun He ₁

Affiliation

胰腺癌（PC）是消化系统恶性程度最高的癌症类型，预后较差。顺铂等化疗是诊断患有晚期或转移性疾病的 PC 患者的最后机会。深入了解 PC 肿瘤发生的分子机制并确定最佳生物标志物来估计化疗敏感性对于 PC 治疗至关重要。人们发现染色质重塑因子 HELLS 在多种癌症中通过表观遗传途径调节各种肿瘤抑制因子。我们通过蛋白质印迹和免疫组织化学染色分析了临床样本中的 HELLS 表达。接下来，我们确定了 HELLS 敲低后肿瘤生长和顺铂敏感性的变化，并通过 RNA 测序、染色质免疫沉淀以及功能获得和丧失检测探索了 PC 中 HELLS 的下游介质。我们发现 HELLS 在 PC 组织中表达上调，与晚期临床分期和不良预后相关，并且 HELLS 的敲低导致肿瘤生长停滞和对顺铂的敏感性增加。从机制上讲，肿瘤抑制因子 TGFBR3 在 HELLS 敲除后显着重新表达；相反，损害 TGFBR3 可以挽救 PC 细胞中 HELLS 敲低介导的效应。因此，我们的数据提供证据表明，HELLS 可以作为潜在的癌基因和合适的生物标志物，通过表观遗传学沉默 PC 中的肿瘤抑制因子 TGFBR3 来评估化疗敏感性。

"点击查看英文标题和摘要"

HELLS, a chromatin remodeler is highly expressed in pancreatic cancer and downregulation of it impairs tumor growth and sensitizes to cisplatin by reexpressing the tumor suppressor TGFBR3

Pancreatic cancer (PC) is the most malignant cancer type in the digestive system with a poor prognosis. Chemotherapy such as cisplatin is the last chance for PC patients diagnosed with advanced or metastatic disease. Obtaining a deep understanding of the molecular mechanism underlying PC tumorigenesis and identifying optimal biomarkers to estimate chemotherapy sensitivity are essential for PC treatment. The chromatin remodeler HELLS was found to regulate various tumor suppressors through an epigenetic pathway in several cancers. We analyzed HELLS expression in clinical samples by Western blotting and immunohistochemical staining. Next, we identified the variation in tumor growth and cisplatin sensitivity after knockdown of HELLS and explored the downstream mediators of HELLS in PC via RNA‐seq, chromatin immunoprecipitation, and gain‐ and loss‐of‐function assays. We found that HELLS is upregulated in PC tissues and correlates with advanced clinical stage and a poor prognosis, and the knockdown of HELLS leads to tumor growth arrest and increased sensitivity to cisplatin. Mechanistically, the tumor suppressor TGFBR3 is markedly reexpressed after HELLS knockdown; conversely, compromising TGFBR3 rescues HELLS knockdown‐mediated effects in PC cells. Thus, our data provide evidence that HELLS can serve as a potential oncogene and suitable biomarker to evaluate chemotherapy sensitivity via epigenetically silencing the tumor suppressor TGFBR3 in PC.

更新日期：2021-01-24

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南